Cargando…
Rituximab Monotherapy versus Rituximab and Bortezomib Combination Therapy for Treatment of Non-paraneoplastic Autoimmune Retinopathy
PURPOSE: To study whether rituximab and bortezomib combination therapy is more effective than rituximab monotherapy in the treatment of non-paraneoplastic autoimmune retinopathy (npAIR). METHODS: Retrospective case series involving six patients with npAIR, taking either rituximab and bortezomib comb...
Autores principales: | Maleki, Arash, Colombo, Amanda, Look-Why, Sydney, Peter Y Chang, BA;, Anesi, Stephen D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PUBLISHED BY KNOWLEDGE E
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806323/ https://www.ncbi.nlm.nih.gov/pubmed/36620716 http://dx.doi.org/10.18502/jovr.v17i4.12304 |
Ejemplares similares
-
Rituximab as a monotherapy or in combination therapy for the treatment of non-paraneoplastic autoimmune retinopathy
por: Maleki, Arash, et al.
Publicado: (2017) -
Efficacy of rituximab in non-paraneoplastic autoimmune retinopathy
por: Boudreault, Katherine, et al.
Publicado: (2017) -
A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE
por: van Dam, Laura S, et al.
Publicado: (2020) -
COVID-19 Recombinant mRNA Vaccines and Serious Ocular Inflammatory Side Effects: Real or Coincidence?
por: Maleki, Arash, et al.
Publicado: (2021) -
B-Scan Ultrasonography Findings in Unilateral Posterior Scleritis
por: Maleki, Arash, et al.
Publicado: (2022)